Arrivent Biopharma Inc (AVBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -80,488 | -69,333 | -36,906 | -51,606 |
| Accounts payable and accrued liabilities | -751 | 1,379 | 2,800 | 293 |
| Other Working Capital | 7,068 | 12,596 | -7,149 | -3,941 |
| Other Operating Activity | 3,959 | -484 | -2,376 | 42,667 |
| Operating Cash Flow | $-70,212 | $-55,842 | $-43,631 | $-12,587 |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | -192,465 | 0 | N/A | N/A |
| Other Investing Activity | 0 | 0 | 0 | -40,000 |
| Investing Cash Flow | $-192,465 | $N/A | $N/A | $-40,000 |
| Cash Flows From Financing Activities | ||||
| Debt Issued | N/A | N/A | N/A | 200 |
| Debt Repayment | N/A | N/A | N/A | -200 |
| Common Stock Issued | 186,581 | 354 | 17 | 2 |
| Other Financing Activity | 0 | 42,505 | 169,706 | 89,865 |
| Financing Cash Flow | $186,581 | $42,859 | $169,723 | $89,867 |
| Beginning Cash Position | 150,389 | 163,372 | 37,280 | N/A |
| End Cash Position | 74,293 | 150,389 | 163,372 | 37,280 |
| Net Cash Flow | $-76,096 | $-12,983 | $126,092 | $37,280 |
| Free Cash Flow | ||||
| Operating Cash Flow | -70,212 | -55,842 | -43,631 | -12,587 |
| Free Cash Flow | -70,212 | -55,842 | -43,631 | -12,587 |